Drugs / Padsevonil
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT04136444 | Oct 2019 → May 2020 | — | UCB Biopharma S.P.R.L. | Terminated | No outcome recorded |
| Phase 1 | NCT04131517 | Oct 2019 → May 2020 | — | UCB Biopharma SRL | Terminated | No outcome recorded |
| Phase 1 | NCT04126343 | Oct 2019 → May 2020 | — | UCB Biopharma S.P.R.L. | Terminated | No outcome recorded |
| Phase 1 | NCT04075409 | Sep → Dec 2019 | — | UCB Biopharma S.P.R.L. | Completed | No outcome recorded |
| Phase 1 | NCT04039919 | Jul 2019 → May 2020 | — | UCB Biopharma S.P.R.L. | Terminated | No outcome recorded |
| Phase 1 | NCT04013191 | Jul → Oct 2019 | — | UCB Biopharma S.P.R.L. | Completed | No outcome recorded |
| Phase 1 | NCT03695094 | Sep 2018 → May 2019 | epilepsy | UCB Biopharma S.P.R.L. | Completed | No outcome recorded |
| Phase 1 | NCT03480243 | Mar → Aug 2018 | — | UCB Biopharma S.P.R.L. | Completed | No outcome recorded |
| Phase 1 | NCT03168984 | May → Aug 2017 | — | UCB Biopharma S.P.R.L. | Completed | No outcome recorded |
| Phase 24 trials · 2 missed | ||||||
| Phase 2 | NCT03370120 | Aug 2018 → Dec 2020 | focal epilepsy | UCB Biopharma SRL | Terminated | No outcome recorded |
| Phase 2 | NCT03373383 | Feb 2018 → Jan 2020 | focal epilepsy | UCB Biopharma S.P.R.L. | Completed | Missed primary |
| Phase 2 | NCT02625090 | Dec 2015 → Nov 2020 | focal epilepsy | UCB Biopharma SRL | Terminated | No outcome recorded |
| Phase 2 | NCT02495844 | Jul 2015 → Feb 2017 | focal epilepsy | UCB Biopharma S.P.R.L. | Completed | Missed primary |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT03739840 | Mar 2019 → Sep 2020 | focal epilepsy | UCB Biopharma SRL | Terminated | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04283136 Comparator | Feb → May 2020 | epilepsy | UCB Biopharma SRL | Withdrawn | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Padsevonil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03373383 ↗ |
| Known as | PSL | “The purpose of the study in Part 1, is to evaluate (under fasted conditions) the plasma pharmacokinetics (PK) of padsevonil (PSL) using 4 PSL product variants against a PSL...” NCT04283136 ↗2“To characterize efficacy, safety/tolerability, and pharmacokinetics of padsevonil (PSL) administered concomitantly with ≤3 antiseizure medications (ASMs) for observable focal...” PMID 36176044 ↗ Oct 2022 “The purpose of the study is to evaluate the pharmacodynamic (PD) interaction between steady-steady treatment with padsevonil (PSL) and Ethanol and the pharmacokinetic (PK)...” NCT04039919 ↗ |
| Known as | UCB-1415943-000 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297521 ↗ |
| Known as | UCB0942 | “Padsevonil (UCB0942)” NCT03480243 ↗ |
| Modality | Small molecule | — CHEMBL4297521 ↗ |
| Route | Oral | “Route of Administration: Oral use” NCT02495844 ↗ |
| Target | CYP2C19 | “Padsevonil was shown to be a time-dependent CYP2C19-inhibitor, weak CYP3A4-inducer, weak inhibitor of P-gp/OCT1/MATE2-K, and potent OCT2-inhibitor.” PMID 38932723 ↗ Jul 2024 |
| Target | CYP3A4 | “Padsevonil was shown to be a time-dependent CYP2C19-inhibitor, weak CYP3A4-inducer, weak inhibitor of P-gp/OCT1/MATE2-K, and potent OCT2-inhibitor.” PMID 38932723 ↗ Jul 2024 |